Accessibility Menu
 
InMed Pharmaceuticals logo

InMed Pharmaceuticals

(NASDAQ) INM

Current Price$0.67
Market Cap$1.88M
Since IPO (2014)-100%
5 Year-100%
1 Year-73%
1 Month-21%

InMed Pharmaceuticals Financials at a Glance

Market Cap

$1.88M

Revenue (TTM)

$5.28M

Net Income (TTM)

$9.07M

EPS (TTM)

$-3.78

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

1.32 (Average)

Price

$0.67

Volume

1,742

Open

$0.68

Previous Close

$0.64

Daily Range

$0.63 - $0.68

52-Week Range

$0.57 - $7.98

INM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InMed Pharmaceuticals

Industry

Pharmaceuticals

Employees

13

CEO

Eric A. Adams

Headquarters

Vancouver, BC V6C 1B4, CA

INM Financials

Key Financial Metrics (TTM)

Gross Margin

26%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-97%

Return on Capital

-69%

Return on Assets

-59%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.88M

Shares Outstanding

2.92M

Volume

1.74K

Short Interest

0.00%

Avg. Volume

115.69K

Financials (TTM)

Gross Profit

$1.71M

Operating Income

$7.92M

EBITDA

$7.26M

Operating Cash Flow

$7.77M

Capital Expenditure

$0.00

Free Cash Flow

$7.77M

Cash & ST Invst.

$15.09M

Total Debt

$1.01M

InMed Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.13M

+1.2%

Gross Profit

$35.91K

-92.2%

Gross Margin

3.19%

N/A

Market Cap

$1.88M

N/A

Market Cap/Employee

$144.59K

N/A

Employees

13

N/A

Net Income

$2.78M

-8.1%

EBITDA

$2.69M

-28.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$8.87M

+149.8%

Accounts Receivable

$251.05K

-33.5%

Inventory

$947.90M

+59639.3%

Long Term Debt

$169.91K

-77.7%

Short Term Debt

$560.18K

-7.2%

Return on Assets

-59.02%

N/A

Return on Invested Capital

-69.22%

N/A

Free Cash Flow

$3.23M

-29.0%

Operating Cash Flow

$3.23M

-29.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNPXGenprex, Inc.
$1.27-1.92%
CNSPCNS Pharmaceuticals, Inc.
$2.17-2.25%
JAGXJaguar Health, Inc.
$0.36-5.62%
BDRXBiodexa Pharmaceuticals Plc
$3.33+2.46%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.49-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.47+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$49.58+0.01%
EOSEEos Energy Enterprises
$5.89-0.01%

Questions About INM

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.